Katherine Tuttle, MD, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington.

 in Denver, Colorado, cohosts Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, welcomed back Katherine Tuttle, MD, of Providence Inland Northwest Health and the University of Washington School of Medicine. 

The group broke down new analyses from the FIND-CKD trial of finerenone in non-diabetic chronic kidney disease (CKD), presented during a dedicated finerenone session. Topics included combination therapy with SGLT2 inhibitors, hyperkalemia, IgA nephropathy, and outcomes across CKD severity.

Kidney Compass: New FIND-CKD Finerenone Data From ASN Kidney Week 2026

Does Finerenone Benefit Patients With CKD Already Taking an SGLT2 Inhibitor?

FIND-CKD randomized 1584 patients with non-diabetic CKD, an eGFR of 25 to below 90 mL/min/1.73 m², and albuminuria on optimized renin-angiotensin system blockade to finerenone or placebo.¹ Finerenone slowed total eGFR decline by 0.7 mL/min/1.73 m² per year versus placebo over 32 months, and the effect was similar in the 17% of patients receiving an SGLT2 inhibitor at baseline (

 for interaction = .71). The composite kidney-cardiovascular outcome was also reduced (hazard ratio, 0.77) regardless of SGLT2 inhibitor use.

00:05 - Welcome and episode overview
01:54 - Finerenone with and without SGLT2 inhibitors in FIND-CKD
03:38 - Hyperkalemia risk and management
07:01 - Finerenone in IgA nephropathy
13:31 - Cardiovascular risk and holistic care in IgAN
15:34 - Sequencing therapies for residual albuminuria
17:58 - Kidney injury biomarkers and innate immunity
22:07 - Finerenone effects across CKD severity

Tuttle called the consistency reassuring, noting the 2 drug classes act on different pathways. Neuen added time-updated analyses, accounting for SGLT2 inhibitor use increasing during the trial, showed the same pattern.

On hyperkalemia, Neuen noted potassium above 6.0 mmol/L occurred in about 4% of patients receiving finerenone compared with 2% with placebo, with few events leading to hospitalization or discontinuation. Across CKD severity, hyperkalemia rates ranged from 5.7% with finerenone vs 5.8% with placebo in the least severe group to 29.4% vs 20.6% in the most severe group.²

“So pay attention and manage it,” Tuttle said. “And most of the time, people can tolerate these therapies, and it’s worth it because these really are kidney, heart, and life-saving therapies.”

What Did FIND-CKD Show for Finerenone in IgA Nephropathy?

Of 1584 FIND-CKD participants, 416 (26%) had IgA nephropathy, and 93% had biopsy confirmation.³ Finerenone reduced urine protein-to-creatinine ratio (UPCR) by 51% versus placebo at month 12 and increased the likelihood of reaching UPCR below 500 mg/g (odds ratio, 6.8; 95% CI, 3.7–13.1).

The effect on total eGFR slope was similar in participants with and without IgA nephropathy (0.6 vs 0.7 mL/min/1.73 m² per year; 

 for interaction = .755).³ Finerenone did not reduce galactose-deficient IgA1 or other immunoglobulins but did lower kidney injury biomarkers, particularly KIM-1 and urinary MMP7.

Wadhwani said the ability to reach proteinuria targets without adding immunosuppression is meaningful, given many patients are diagnosed with advanced CKD. Tuttle pointed to cardiovascular disease, particularly heart failure, as the leading cause of death in this population.

Asked how to prioritize therapies, Tuttle advised letting residual albuminuria guide add-on treatment. She urged clinicians to “aspire to extinguish albuminuria even in people with IgA nephropathy, and not just to protect their kidneys, but protect the rest of them.” For patients at risk of heart failure, she said she would favor finerenone, while noting the opinion is not based on a head-to-head trial.

On the biomarker data, Tuttle said reductions in KIM-1 and MMP7 support a complementary mechanism targeting tubulointerstitial inflammation and fibrosis driven by innate immunity, which immunologic therapies leave unaddressed.

Does Finerenone Work Across All Stages of CKD Severity?

In an analysis presented by Tuttle, finerenone reduced the rate of eGFR decline and the composite kidney-cardiovascular outcome vs placebo irrespective of baseline eGFR and urine albumin-to-creatinine ratio.² Tuttle also described a pooled individual participant–level analysis of FIDELIO-DKD, FIGARO-DKD, and FIND-CKD showing consistent benefits, with greater kidney benefit in high-risk groups and greater cardiovascular benefit in lower-risk groups. She said the findings also carry a message for cardiologists, who often manage lower-risk patients, as finerenone can markedly reduce cardiovascular complications regardless of diabetes status.

“So no therapeutic inertia,” Tuttle said. “Initiate finerenone because it preserves kidney function in people with advanced CKD, where kidney failure is their most imminent risk.”

 include AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, and others. Disclosures for 

 include Boehringer Ingelheim, Calliditas Therapeutics, GSK, Otsuka Pharmaceutical Co., Travere Therapeutics, and others. Disclosures for 

 include Eli Lilly and Company, Boehringer Ingelheim, Astra Zeneca, Gilead, Goldfinch Bio, Novo Nordisk, Travere Therapeutics, and Bayer.

Cherney D, Heerspink HJL, Agarwal R, et al. Finerenone in patients with CKD by SGLT2 inhibitor treatment: a FIND-CKD analysis. Presented at: ASN Kidney Week 2026; October 21-25, 2026; Denver, CO. doi:10.1681/ASN.2026a8de76t0

Tuttle KR, Heerspink HJL, Agarwal R, et al. Effects of finerenone on clinical outcomes by CKD severity: a FIND-CKD analysis. Presented at: ASN Kidney Week 2026; October 21-25, 2026; Denver, CO. doi:10.1681/ASN.2026aepxagfn

Neuen BL, Barratt J, Floege J, et al. Finerenone in patients with IgA nephropathy: a FIND-CKD analysis. Presented at: ASN Kidney Week 2026; October 21-25, 2026; Denver, CO. doi:10.1681/ASN.2026q6qqpem2

Podcasts

Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Kidney Compass: Navigating Clinical Trials

Hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, Kidney Compass: Navigating Clinical Trials is a regular podcast exploring and breaking down the latest updates and nuances of clinical trials in nephrology. By listening to Kidney Compass, you'll get the guidance you need to navigate the changing landscape of clinical trials across the spectrum of kidney disease. 

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Steven M. Brunelli, MD, MSCE, is the vice president and medical director of health analytics and insights at DaVita Clinical Research

, greater cumulative exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with progressive weight reduction and a lower hospitalization burden.¹

American Society of Nephrology (ASN) Kidney Week 2026

 in Denver, Colorado, by Steven M. Brunelli, MD, MSCE, an author on the study and vice president and medical director of health analytics and insights at DaVita Clinical Research, the retrospective cohort data suggest the weight loss seen with GLP-1 RAs in the general population may extend to patients on PD. The investigators noted that prospective studies are needed to confirm long-term effects in this population.

GLP-1s Tied to Weight Loss in Peritoneal Dialysis, With Steven Brunelli, MD

Patients on PD with type 2 diabetes face cardiovascular risk, a substantial metabolic burden from dialysate glucose exposure and progressive loss of residual kidney function.¹ In the FLOW trial, semaglutide reduced the risk of death from cardiovascular causes in patients with type 2 diabetes and 

, but evidence on GLP-1 RA use in PD populations remains limited.¹,²

“In general, dialysis patients, and in particular peritoneal dialysis patients, don’t make it into the landmark clinical trials,” Brunelli said in an interview with 

. “When there’s a big breakthrough, things like GLP-1s that are radically transforming care for patients, we don’t know whether those findings apply in this subset of patients who have their own unique challenges and also their own unique biology.”

How Investigators Tracked GLP-1 RA Exposure in Peritoneal Dialysis

To address this gap in research, the team conducted a retrospective cohort study of 5,897 adults with type 2 diabetes who initiated PD between April 2021 and September 2024. Of those, 516 (8.7%) initiated a GLP-1 RA.¹

Patients were followed from day 90 after PD start, and patient time was assigned to GLP-1 RA use or control based on prescription data. Marginal structural models estimated the average treatment effect in the overlap population, using stabilized inverse probability weights to account for time-varying treatment assignment and censoring.¹

The primary outcome of interest was relative weight change. Secondary outcomes included hospitalization, body surface area (BSA) indexed ultrafiltration and urine output, while HbA1c and mortality were exploratory.¹

GLP-1 RA Exposure, Weight Change and Hospitalization Results

Increasing cumulative GLP-1 RA exposure was associated with progressive weight reduction (−1.19 percentage points [pp]; 95% CI, −1.97 to −0.42; 

 = .003), with a dose response of −0.73 pp per exposure quarter (

 < .001). The association strengthened when the analysis was restricted to new users (−1.69 pp; 

Greater cumulative exposure was also associated with a lower modeled hospitalization burden (incidence rate ratio, 0.935 per exposure quarter; 

 = .004). BSA indexed ultrafiltration and urine output showed no significant associations.¹

Mortality estimates were directionally protective but imprecise (HR, 0.706; 

 = .33). HbA1c analyses violated parallel trend assumptions and were interpreted descriptively because of confounding by indication.¹

Brunelli emphasized that the observational design means the findings should inform, rather than settle, clinical decisions, and said he hopes the work builds momentum for a dedicated trial in PD.

“It’s still an observational study. It’s not the same as a clinical trial,” Brunelli said. “In the meantime, for patients who otherwise would be good GLP-1 candidates, our data are consistent with the idea that we shouldn’t deny the patients the GLP-1 specifically because they’re on peritoneal dialysis.”

Editor’s Note: Disclosures for Brunelli include DaVita, Inc.

Luo J, Sibbel S, Weinhandl ED, et al. GLP-1 receptor agonist exposure and longitudinal outcomes in patients with type 2 diabetes initiating peritoneal dialysis. Abstract presented at: American Society of Nephrology Kidney Week 2026; October 21-25, 2026; Denver, Colorado. Poster FR-PO1115. doi:10.1681/ASN.202657kx8n1h

Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. 

. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347

Videos

Longer GLP-1 RA exposure was also associated with a lower hospitalization burden in a cohort of 5,897 patients with type 2 diabetes.

Chronic Kidney Disease

Jessica Kendrick, MD, MPH, is a Professor of Medicine-Renal Med Diseases/Hypertension at University of Colorado Anschutz.

Upacicalcet, an investigational intravenous calcimimetic, significantly increased the proportion of patients receiving hemodialysis with secondary hyperparathyroidism (SHPT) who achieved at least a 30% reduction in intact parathyroid hormone (iPTH) versus placebo, according to results from the identical phase 3 PATH-1 and PATH-2 trials.

Jessica Kendrick, MD, MPH, of the University of Colorado Anschutz Medical Campus, discussed the findings with 

Upacicalcet for Secondary Hyperparathyroidism on Dialysis

Existing calcimimetics are limited by hypocalcemia and gastrointestinal adverse effects, which reduce adherence, Kendrick explained. Upacicalcet is a positive allosteric modulator of the calcium-sensing receptor and is already approved for SHPT in Japan.

 Pathalys Pharma is developing the agent for a potential US regulatory submission.

“It only works if the extracellular calcium levels are at a physiologic level,” Kendrick said. “So if they’re actually low, then it does not work, which is unlike other previous calcimimetics.”

How Effective Was Upacicalcet in the PATH-1 and PATH-2 Trials?

PATH-1 and PATH-2 were identical, double-blind, placebo-controlled trials conducted in parallel in 768 patients receiving hemodialysis with SHPT and baseline iPTH levels of 400 to 1500 pg/mL.

 Participants were randomized 2:1 to intravenous upacicalcet (n = 510) or placebo (n = 258) after each hemodialysis session for 27 weeks, with dosing titrated based on iPTH and corrected serum calcium.

The primary end point was the proportion of participants achieving at least a 30% decrease from baseline in mean iPTH during the efficacy assessment period, weeks 22 to 27. Mean age was 58.6 years in PATH-1 and 59.2 years in PATH-2, and 66.3% and 59.7% of participants were male, respectively.

In PATH-1, 42.1% (101/239) of upacicalcet-treated participants met the primary end point vs 16.8% (20/120) receiving placebo, a difference of 25.3% (95% CI, 16.2%–34.5%; 

 < .0001). In PATH-2, the corresponding rates were 43.5% (118/271) vs 17.4% (24/138), a difference of 26.1% (95% CI, 17.4%–34.8%; 

Upacicalcet was also superior to placebo for the key secondary end point of at least a 50% reduction in iPTH, according to Kendrick.

What Was the Safety Profile of Upacicalcet in Hemodialysis?

Adverse events occurred in 69.9% of upacicalcet-treated participants versus 60.8% receiving placebo in PATH-1, and in 71.6% versus 59.4% in PATH-2.¹ Serious adverse events were similar between groups, at 25.5% versus 24.2% in PATH-1 and 23.2% versus 21.7% in PATH-2. Gastrointestinal symptoms were low and similar between groups.

Asymptomatic decreased blood calcium was the most frequent adverse event, occurring in 23.4% compared with 8.3% of participants in PATH-1 and 19.2% vs 10.9% in PATH-2. Symptomatic hypocalcemia with upacicalcet occurred in 0.8% (2/239) of participants in PATH-1 and 2.2% (6/271) in PATH-2.

Kendrick noted upacicalcet is removed during the next dialysis session and does not accumulate. This allows clinicians to adjust the next dose in real time when calcium levels fall, rather than waiting a week or more for the drug to clear.

“So I think what this drug gives us is better clinical flexibility than the current options,” Kendrick said. She added lower rates of hypocalcemia and gastrointestinal effects may improve adherence and reduce treatment interruptions.

Longer-term questions remain. Kendrick said data on whether upacicalcet reduces cardiovascular events or fractures are not yet available, as the PATH trials assessed biochemical endpoints only.

Kendrick JB, Wolf M, Tirmenstajn Jankovic BH, et al. Efficacy and safety of upacicalcet in patients with secondary hyperparathyroidism (SHPT) on hemodialysis: two randomized controlled clinical trials (RCTs). Presented at: ASN Kidney Week 2026; October 21-25, 2026; Denver, CO. doi:10.1681/ASN.2026s02jzt6e

Waldron J. Pathalys raises $105M series B to prepare Japan-approved kidney disease drug for FDA. Fierce Biotech. Published August 20, 2024. Accessed October 24, 2026. 

https://www.fiercebiotech.com/biotech/pathalys-raises-105m-series-b-prepare-japan-approved-kidney-disease-drug-fda

Jessica Kendrick, MD, MPH, discusses phase 3 PATH data showing upacicalcet reduced iPTH in hemodialysis patients with secondary hyperparathyroidism.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Christopher Chan, MD, is director of the division of nephrology, professor of medicine, and R Fraser Elliott Chair in Nephrology at Toronto General Hospital, University Health Network.

An automated digital counseling program did not increase overall uptake of home kidney replacement therapy (KRT) in patients with 

, but patients who were motivationally ready at baseline were substantially more likely to initiate home KRT with the intervention, according to the ODYSSEE-Kidney Health trial.

Christopher Chan, MD, of University Health Network in Toronto, presented the findings at 

“We need to know our patients’ preference, we need to know our patients’ goals, and we also need to match the education towards their goals and preferences,” Chan told 

Can Digital Counseling Boost Home Dialysis Uptake? Christopher Chan, MD

Task force guidelines advocate informed decision-making about home-based KRT, including home peritoneal dialysis, home hemodialysis, and preemptive kidney transplant evaluation.

 ODYSSEE is a digital cognitive behavioral therapy platform previously studied in hypertension and heart failure, Chan explained, designed to support education, self-efficacy, and patient activation.

Did Digital Counseling Increase Home Kidney Replacement Therapy Uptake?

The 2-arm, single-blind randomized controlled trial assigned 158 patients with CKD in a 1:1 ratio to ODYSSEE plus usual care or usual care alone. Eligible patients had a 2-year kidney failure risk above 10% using the 4-variable kidney failure risk equation. The primary outcome was a composite of home peritoneal dialysis, home hemodialysis, or evaluation for kidney transplant, monitored for a median of 12 months.

Participants were 70% male, with a mean age of 62 years and a mean 2-year kidney failure risk of 45%. At baseline, 16% reported being motivationally ready to act, measured with a validated readiness score.

Overall, 32 patients initiated home KRT, and incidence did not differ by randomized group (odds ratio [OR], 1.5; 95% CI, 0.7–3.2). However, a significant interaction emerged between randomized group and baseline readiness (OR, 16.6; 95% CI, 1.7–157.2).

Results showed the estimated probability of initiating home KRT was 0.75 among ready patients receiving ODYSSEE, compared with 0.33 among ready patients receiving usual care. In a Cox proportional hazards model, ODYSSEE was associated with a shorter time to home KRT among patients motivationally ready at baseline.

What Role Does Patient Readiness Play in Home Dialysis Decisions?

In a post hoc Bayesian analysis, ODYSSEE patients with baseline readiness had higher odds of initiating home KRT (OR, 4.71; 95% credible interval, 1.65–13.37), with a 99.8% posterior probability of benefit. The analysis estimated an 89% posterior probability baseline readiness positively modified the effect of ODYSSEE.

The investigators acknowledged the trial was underpowered to evaluate its primary outcome.

 They concluded patient motivation is prospectively associated with initiation of home KRT or transplant evaluation, raising the challenge of building motivation-enhancing procedures into digital counseling.

Chan said the findings challenge the common view of CKD education as a single class or session. Effective education requires time to build a relationship and allow patients the mental space to change, whether delivered digitally or face to face, he explained.

He emphasized digital tools should supplement rather than replace in-person care, noting time away from the clinic far exceeds face-to-face encounters. “We need our clinical encounters and also additional supplemental form of education,” Chan said.

Looking ahead, Chan described developing additional digital adjuncts and education series to augment existing clinical services, including platforms designed for patients living with multiple chronic conditions.

Chan CT, Nolan R. The ODYSSEE-Kidney Health trial for home kidney replacement therapy (KRT). Poster presented at: ASN Kidney Week 2026; October 21-25, 2026; Denver, CO. doi:10.1681/ASN.2026v6z6x0b9

ODYSSEE-Kidney Health trial. ClinicalTrials.gov identifier: NCT06274710. Accessed October 24, 2026. 

https://clinicaltrials.gov/study/NCT06274710

Christopher Chan, MD, discusses why digital counseling was linked to higher home KRT uptake only among motivationally ready patients with CKD.

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Karin Gerritsen, MD, PhD, internist-nephrologist and clinical scientist at University Medical Center (UMC) Utrecht

A portable sorbent hemodialysis system met its prespecified adequacy threshold for single-pool Kt/V, with no serious adverse device effects, in the first 2 phases of the pivotal RENEW-HD trial.¹

Karin Gerritsen, MD, PhD, of the Department of Nephrology and Hypertension at University Medical Center (UMC) Utrecht and senior author of the study, discussed the data from the 

 in Denver, Colorado. Fluid, electrolyte, and acid-base parameters remained generally stable in the single-arm, open-label trial, and investigators plan to lower dialysate calcium before evaluating more autonomous use.

RENEW-HD: Portable Hemodialysis Data, With Karin Gerritsen, MD, PhD

 that the system was developed in response to “the strong unmet need among dialysis patients for more flexibility, more autonomy, a bit more freedom.”

How the Neokidney Sorbent System Regenerates Dialysate

Conventional hemodialysis requires substantial infrastructure and water, which limits patient mobility.¹ Standard systems use ≥30 L of dialysate per session, and treatment typically runs 4 hours, 3 times per week.² According to Gerritsen, other low-flow home systems still run dialysate in a single pass, which keeps fluid volumes high.

The roughly 13 kg Neokidney instead regenerates 4.5 L of dialysate through sorbents in a closed loop. Urease in the cartridge breaks down urea, and the released ammonium is captured by zirconium phosphate. The device runs at a fixed dialysate flow of 300 mL/min and does not require a connection to water supply or drainage.

RENEW-HD is a pivotal, prospective, open-label, single-arm investigation in adults on maintenance hemodialysis at 4 European centers. In phase 1, 4 participants received assisted in-center treatment with the Neokidney for up to 11 sessions over 3 weeks.

In phase 2, participants received assisted in-center treatment for up to 30 days, at 4 to 7 two-hour sessions per week, with a target of 500 sessions. The primary efficacy endpoint was mean single-pool Kt/V (spKt/V), with adequate performance defined as a lower bound of the 2-sided 95% confidence interval (CI) ≥0.60. Additional outcomes included serious adverse device effects (SADEs), vital and biochemical parameters, and ultrafiltration accuracy.

Neokidney Kt/V and Ultrafiltration Results

As of August 31, 2026, 29 participants had completed 474 sessions, 95% of those planned for phases 1 and 2.¹

In the data presented at the meeting, mean spKt/V was 0.74 per 2-hour treatment, with the lower bound of the CI above 0.60. Gerritsen reported a mean weekly standardized Kt/V of 2.19, not accounting for residual kidney function. Ultrafiltration volumes calculated from body weight agreed with device-reported volumes in 95% of cases.

Vital parameters and blood biochemistry, including sodium and bicarbonate, remained generally stable over the 4-week treatment period.¹ Gerritsen noted that sodium declined slightly, which investigators attributed to a shift toward each patient’s individual sodium set point, as dialysate sodium equilibrates with plasma. Phosphate rose slightly while reduction ratios stayed high, which investigators believe may reflect increased protein intake; this is still under investigation.

Neokidney Safety Findings and Sorbent Exhaustion Alarms

No SADEs or device deficiencies with the potential to cause a serious adverse event occurred, and no hyperammonemia was observed in any of the 474 sessions.¹ In the abstract, sorbent exhaustion occurred once, at the end of a session in which estimated urea removal exceeded the system’s specified capacity, and was correctly detected by the device.

In the updated data presented at the meeting, Gerritsen reported 5 sessions that ended early when cartridge exhaustion triggered an ammonium alarm, which she described as the intended safety response. In each case, urea removal exceeded the cartridge specifications and no hyperammonemia occurred. Two additional sessions ended early near their scheduled end because of system errors after abrupt patient movement.

Dialysate Calcium Elevations Ahead of Phase 3

The most notable adverse device effect involved calcium. Gerritsen reported that ionized calcium rose above 1.5 mmol/L in 3 patients without symptoms, and 1 patient was withdrawn after 2 weeks. In most others, predialysis calcium rose gradually before stabilizing at approximately 1.3 mmol/L.

Investigators traced this to a dialysate calcium concentration >1.6 mmol/L and plan to adjust it for phase 3. Three patients also reported taste disturbances, the cause of which is being investigated.

Next Step: Autonomous Use and Home Certification

Investigators concluded that the dialysis dose was consistent with current adequacy targets, supporting the feasibility of the system.¹ The phase 1 and 2 data will support an application for CE certification for in-center use in Europe. Phase 3, expected to begin by the end of 2026, will evaluate more autonomous use across approximately 500 additional sessions to support certification for home use.

“We think these results provide a solid base to proceed to the third stage, the autonomous use of the device,” Gerritsen said.

Editor’s Note: RENEW-HD was funded by Nextkidney B.V.

Bolhuis DP, Bach D, Bluechel C, et al. Efficacy and safety of the Neokidney portable hemodialysis system: preliminary phase 1 and 2 results of the RENEW-HD trial. Late-breaking abstract presented at: American Society of Nephrology Kidney Week 2026; October 21-25, 2026; Denver, CO. doi:10.1681/ASN.2026yrjf6rv2

UMC Utrecht. Patients test a portable artificial kidney at home for the first time. Published January 2026. Accessed October 24, 2026. 

https://research.umcutrecht.nl/news/patients-test-a-portable-artificial-kidney-at-home-for-the-first-time/

Early RENEW-HD data support moving the 13 kg Neokidney to autonomous use testing, with dialysate calcium adjustments planned.

Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Kidney Compass: Final 2-Year TELIGAN Data for Telitacicept in IgA Nephropathy

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Articles

A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.

Sparsentan Lowers Inflammatory, Complement Biomarkers in IgAN

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.

Type 1 Diabetes

Type 2 Diabetes

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Jean Bourbeau, MD, professor of medicine at McGill University.

Jean Bourbeau, MD, says AI analysis of CT scans is not ready for routine use but could reshape early COPD diagnosis as GOLD expands its AI guidance.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

AI Could Help Find Undiagnosed COPD on Lung Cancer Screening CT

Hugh Gallagher, MD, is a Consultant Nephrologist at Epsom and St Helier NHS Trust and a Visiting Professor in the Academic Unit of Primary Care and Population Sciences at the University of Southampton.

Hugh Gallagher, MBBS, PhD, discusses a 27% lower point estimate for cardiovascular events with aspirin that was not significant.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

ATTACK: Should Patients With CKD Start Aspirin for Primary Prevention?

Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.

Tenapanor Lowers Serum Phosphate Regardless of Binder Use in Dialysis

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.

FDA News

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

FDA Approves Subcutaneous Risankizumab Induction for Crohn’s Disease

Sarina Berger Elmariah, MD, PhD, MPH, reviews 3-year nemolizumab data showing deeper skin clearance and lasting itch relief in atopic dermatitis responders.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

3-Year Nemolizumab Data in Atopic Dermatitis, With Sarina Elmariah, MD, PhD

Professor of medicine and director of the Pulmonary Hypertension Program at University of Cincinnati Health

Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.

Latest News

Kidney Compass: New FIND-CKD Finerenone Data From ASN Kidney Week 2026

GLP-1s Tied to Weight Loss in Peritoneal Dialysis, With Steven Brunelli, MD

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

RENEW-HD: Portable Hemodialysis Data, With Karin Gerritsen, MD, PhD